Research Initiatives/Clinical Trials

Current Clinical Trials

• Lundbeck Protocol 19356A: Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of IV Eptinezumab in Adolescents (12-17 years) for the Preventive Treatment of Chronic Migraine
• Lundbeck Protocol 19357A: Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Eptinezumab in Pediatric patients (6 to 17 years) for the Preventive Treatment of Episodic Migraine
• Lundbeck Protocol 19379A: Long-term, Open-Label (Dose-Blinded), Extension Study of Eptinezumab in Children and Adolescents with Chronic or Episodic Migraine
• Pfizer Protocol BHV3000-311: Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of Rimegepant for the treatment of migraine (with or without aura) in children and adolescents ≥ 6 to <18 years of age
• Pfizer Protocol BHV3000-312: Phase 3, multicenter, open-label study to assess the long-term safety and tolerability of Rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < 18 years of age
• Pfizer Protocol C5301023: A Phase 1, Multicenter, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Zavegepant in Children 6 to Less Than 12 Years of Age with History of Migraine- In start-up process- expected start July
• AbbVie Protocol M23-714: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the
• Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with
• an Open-Label Extension
• Merz Protocol M602011084: A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of chronic migraine
• Merz Protocol M602011085: A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of episodic migraine.
• AbbVie Protocol P25-590: Phases: Prodrome in the Real World: Assessing Ubrogepant Acute Use
• Lundbeck 20668A: Interventional, open-label trial, investigating the effectiveness of Eptinezumab in participants with migraine and previous inadequate response to CGRP-targeting therapies
• Kallyope Protocol K-304 P005: A Multicenter, Long-Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
• Kallyope Protocol K-304 P003: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of Elismetrep (K-304) in the Acute Treatment of Migraine

True North Clinical Research Foundation is seeking new participants to advance and treat neurological diseases and disorders. please call our research team at to schedule an appointment or click to request an appointment.

Current Clinical Trials

• Tian Medical LLC- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel, 20 Week Study of Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine (Protocol 16-001TI)
• Biohaven Pharmaceuticals, Inc.- A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention (Protocol BHV3500-302)
• Biohaven Pharmaceuticals, Inc.- Phase 3, Multicenter, Randomized, Double-Blind, Group Sequential, Placebo-Controlled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine (with or without aura) in Children and Adolescents 6-18 Years of Age (Protocol BHV3000-311)
• Biohaven Pharmaceuticals, Inc.- Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (with or without aura) in Children and Adolescents 6-18 Years of Age (Protocol BHV3000-312)
• Satsuma Pharmaceuticals, Inc- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine (Protocol STS101-007)

True North Clinical Research Foundation is seeking new participants to advance and treat neurological diseases and disorders. please call our research team at to schedule an appointment or click to request an appointment.

Current Clinical Trials

Novartis Protocol COMB157Q12301: An open-label, randomized, parallel group, non-inferiority study to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new maintenance dosing regimen of ofatumumab, followed by extended treatment in participants with relapsing multiple sclerosis- expected start June

Novartis Protocol CLOU064C12304: A Randomized, Double Blind, Double Dummy, Placebo Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants with Relapsing Multiple Sclerosis, Followed by Extended Treatment with Open-Label Remibrutinib

True North Clinical Research Foundation is seeking new participants to advance and treat neurological diseases and disorders. please call our research team at to schedule an appointment or click to request an appointment.

Current Clinical Trials

AbbVie Protocol M25-850: A Phase 2b/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AGN 151607 DP (USAN: gemibotuliniumtoxinA) for the Treatment of Upper Limb Essential Tremor in Adults

True North Clinical Research Foundation is seeking new participants to advance and treat neurological diseases and disorders. please call our research team at to schedule an appointment or click to request an appointment.

Current Clinical Trials

Theranica Protocol TCH-200: Open label use of Nerivio for management of Temporomandibular disorders.

If you wish to be advised on the most appropriate treatment, please call to schedule an appointment or click to request an appointment online.